Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects

Journal of Nutrition

Volumn 127, Issue 1, 1997, Pages 117-121

  Basu, Tapan K ^a   Mann, Sarabjit ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

hyperhomocysteinemia; hypocysteinemia; hypolipidemic actions; niacin; rats; sulfur amino acids; vitamin B 6

Indexed keywords

HOMOCYSTEINE; NICOTINIC ACID; PYRIDOXINE; SULFUR ACID AMIDE;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; HYPERHOMOCYSTEINEMIA; MALE; METABOLIC REGULATION; NONHUMAN; RAT; VITAMIN INTAKE;

ANIMALIA;

EID: 0031024209     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/127.1.117     Document Type: Article

References (28)

1. Blankenhorn, D. H., Nessim, S. A., Johnson, R. L., Sanmarco, V. E., Azen, S. P. & Cashin-Hemphill, L. (1987) Beneficial effects of combined cofibrate-niacin therapy on coronary atherosclerosis and coronary venous bypass graft. J. Am. Med. Assoc. 275: 3233-3240.
2. Bleiler, R. E. & Schedl, H. P. (1962) Creatinine excretion: variability and relationship to diet and body size. J. Lab. Clin. Med. 59: 945-955.
3. Brattsrom, L. E. (1986) Vitamins as homocysteine-lowering agents. J. Nutr. 126: 1276S-1280S.
4. Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. J. Am. Med. Assoc. 231: 360-381.
5. Coull, B. M., Malinow, M. R., Beamer, N., Sexton, G., Nordt, F. & De Garmo, P. (1990) Elevated plasma homocysteine concentration as a possible independent risk factor for stroke. Stroke 21: 572-576.
6. DiPalma, J. R. & Thayer, W. S. (1991) Use of niacin as a drug. Annu. Rev. Nutr. 11: 169-187.
7. Drood, J. M., Zimetbaum, P. J. & Frishman W. H. (1991) Nicotinic acid for the treatment of hyperlipoproteinemia. J. Clin. Pharmacol. 31: 641-650.
8. Frildwald, W. T., Levy, R. I. & Fredrickson, D. S. (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-501.
9. Grundy, S. M., Mok, H.Y.I., Zech, L. & Berman, M. (1981) Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22: 24-26.
10. Harpel, P. C., Zhang, X. & Borth, W. (1996) Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J. Nutr. 126: 1285S-1289S.
11. Jones, B. N. & Gilligan, J. P. (1983) O-Phthaldialdehyde precolumn derivatization and reverse phase high performance liquid chromatography of polypeptide hydrolysates and physiological fluids. J. Chromatogr. 266: 471-482.
12. Kaijser, L., Eklund, B., Olson, A. G. & Carlson, L. A. (1979) Dissociation of the effects of nicotinic acid in vasodilation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med. Biol. 57: 114-117.
13. Kane, J. P., Malloy, M. J., Tun, P., Phillips, N. R., Freedman, D. D., Williams, M. L., Rowe, J. S. & Havel, R. J. (1981) Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N. Engl. J. Med. 304: 251-258.
14. Knopp, B. H., Ginsberg, J., Albers, J. J., Hoff, C., Ogilvie, J. T., Warnick, G. R., Burrows, E., Retzlaff, B. & Prole, M. (1985) Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34: 642-650.
15. Kuo, P. T., Tole, J. F., Schaaf, J. A., Jones, A., Wilson, A. C., Kostis J. B. & Moreyra, A. E. (1987) Extracranial carotid artery disease in patients with familial hypercholesterolemia and coronary artery disease treated with colestipol and nicotinic acid. Stroke 18: 716-721.
16. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38: 263-274.
17. Olszewski, A. J. & McCully, K. S. (1993) Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radical Biol. & Med. 14: 683-693.
18. Perry, R. (1986) Contemporary recommendations for evaluating and treating hyperlipidemia. Clin. Pharm. 5: 113-127.
19. Shibata K. & Matsuo, H. (1989) Correlation between niacin equivalent intake and urinary excretion of its metabolites, N′-methylnicotinamide, N′-methyl-2-pyridone-5-carboxamide, and N′-methyl-4-pyridone-3-carboxamide, in humans consuming a self-selected food. Am. J. Clin. Nutr. 50: 114-119.
20. Shin-Buckring, Y., Rasshofer, R. & Endres, W. (1981) A new enzymatic method for pyridoxal-5′-phosphate determination. J. Inherited Metab. Dis. 4: 123-124.
21. Steel, R.G.D. & Torrie, J. H. (1980) Principles and Procedures of Statistics: A Biometrical Approach, 2nd ed., pp. 67-119. McGraw-Hill, New York, NY.
22. Stipanuk, M. H. (1986) Metabolism of sulfur-containing amino acids. Annu. Rev. Nutr. 6: 179-209.
23. Sugermann, A. A. & Clark, C. G. (1974) Jaundice following the administration of niacin. J. Am. Med. Assoc. 228: 202-203.
24. Taylor, L. M., DeFrang, R. D., Harris, E. J. & Porter, J. M. (1991) The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J. Vasc. Surg. 13: 128-136.
25. Ubbink, J. B., Delport, R. & Vermaak, W.J.H. (1996) Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J. Nutr. 126: 1254S-1257S.
26. Ubbink, J. B., Vermaak, W.J.H., Van der Merwe, A. & Becker, P. J. (1993) Vitamin B-12, vitamin B-6 and folate nutritional status in men with hyperhomocysteinemia. Am. J. Clin. Nutr. 57: 47-53.
27. Ueland, P. M. & Refsum, H. (1989) Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin Med. 114: 473-501.
28. 3. N. Engl. J. Med. 289: 1180-1182.